二乙基(2R)-2-氯琥珀酸盐 | 377751-50-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 二乙基(2R)-2-氯琥珀酸盐
• 英文名称: D-Chlorbernsteinsaeurediethylester
• 英文别名: Diethyl (2r)-2-chlorosuccinate；diethyl (2R)-2-chlorobutanedioate
• CAS: 377751-50-3
• 化学式: C₈H₁₃ClO₄
• 分子量: 208.642
• InChiKey: JWJDXJCSVYLGDD-ZCFIWIBFSA-N

物化性质

• 沸点：
  252.9±20.0 °C(Predicted)
• 密度：
  1.163±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives
  申请人：——

  公开号：US20040044225A1

  公开（公告）日：2004-03-04

  Disclosed are processes for producing a (2S) or (2R) 4-oxo-chroman-2-yl acyl compounds and chroman-2-yl acyl compounds, esters or amides thereof as well as derivatives thereof. Such processes may involve chiral synthesis or achiral synthesis, preferably coupled with a resolution procedure. Such compounds, particularly (2S) or (2R) acetic acid esters, are useful intermedates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors. Further disclosed are processes for making derivatives of such substantially pure, or enhanced compositions of single (2R) or (2S) enantiomer intermediates or processes for producing final products or salts from such desired enantiomers.

  本发明涉及制备（2S）或（2R）4-氧代-2-基香豆素酰基化合物和香豆素酰基化合物、酯或酰胺以及它们的衍生物的方法。这些方法可以涉及手性合成或非手性合成，优选与分离程序相结合。这些化合物，特别是（2S）或（2R）乙酸酯，可用作生产血小板聚集抑制剂的中间体，或者它们本身就是强效的血小板聚集抑制剂。本发明还涉及制备这些纯度高的单一（2R）或（2S）对映体中间体的衍生物的方法，或者从这些所需对映体制备最终产品或盐的方法。
• [EN] CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES<br/>[FR] SYNTHESE CHIRALE ET ACHIRALE DE CHROMANES SUBSTITUES PAR 2-ACYLE ET LEURS DERIVES
  申请人：COR THERAPEUTICS INC

  公开号：WO2001092249A2

  公开（公告）日：2001-12-06

  Disclosed are processes for producing a (2S) or (2R) 4-oxo-chroman-2-yl acyl compounds and chroman-2-yl acyl compounds, esters or amides thereof as well as derivatives thereof. Such processes may involve chiral synthesis or achiral synthesis, preferably coupled with a resolution procedure. Such compounds, particularly (2S) or (2R) acetic acid esters, are useful intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors. Further disclosed are processes for making derivatives of such substantially pure, or enhanced compositions of single (2R) or (2S) enantiomer intermediates or processes for producing final products or salts from such desired enantiomers.